TIDMETX
RNS Number : 4811A
e-Therapeutics plc
02 June 2021
e-therapeutics plc
("e-therapeutics" or "the Company")
Senior Management Appointment and Grant of Options
Oxford, 2 June 2021 - e-therapeutics plc (AIM: ETX), the drug
discovery company, is pleased to announce the appointment of Alison
Gallafent as Head of Intellectual Property for the Company, and a
grant of options to certain members of the senior management.
Alison Gallafent is a UK Chartered Patent Attorney and European
Patent Attorney, who brings considerable intellectual property
expertise to e-therapeutics, with over 20 years of experience in
the pharmaceutical and biotech industries.
Alison has previously worked as in-house Patent Counsel for a
range of pharmaceutical companies, such as Merck and Co., Glaxo
Wellcome, PLIVA and more recently as Head of IP at Silence
Therapeutics plc. She has also held senior patent attorney roles in
several leading international law firms and has successfully
represented many international pharmaceutical companies in high
profile and pivotal patent cases before the European Patent
Office.
Alison also brings a wealth of knowledge of the siRNA patent
landscape to the Company, and how to strategically operate in this
field.
Alison Gallafent, Head of Intellectual Property, said: "I am
delighted to be joining the e-therapeutics team. I am very excited
to be part of the process of creating meaningful Intellectual
Property assets for the Company at this stage of its development,
based on using the Company's computational biology drug discovery
platform to develop clinically validated siRNA drugs."
Ali Mortazavi, Chief Executive Officer, commented: "We are
delighted to welcome Alison to e- therapeutics at this point in the
Company's evolution. The combination of her broad industry and RNAi
expertise will be a major addition to the team."
Grant of Options
As part of the Company's Long Term Incentive Plan, the Board has
granted options over 500,000 and 1,250,000 ordinary shares of 0.1
pence each respectively to Alison Gallafent and Karl Keegan, Chief
Financial Officer, who joined the Company in March 2021.
The options granted have an exercise price of GBP0.12, vest
after three years and expire 10 years from the date of grant.
Vesting or exercise of the options is not dependent on performance
criteria.
Following this grant of options, the total number of ordinary
shares under option is 25,772,836, representing 6.13 per cent. of
the Company's issued share capital.
-Ends-
Enquiries:
e-therapeutics plc Tel: +44 (0)1993 883
125
Ali Mortazavi, CEO www.etherapeutics.co.uk
Karl Keegan, CFO
SP Angel Corporate Finance LLP
Nominated Adviser and Broker Tel: +44(0)20 3470
0470
Matthew Johnson/Caroline Rowe (Corporate
Finance)
Vadim Alexandre/Rob Rees (Corporate
Broking)
About e-therapeutics plc
e-therapeutics plc is an Oxford, UK-based company with a
powerful computer-based approach to drug discovery, founded on its
industry-leading expertise in network biology to fully capture
disease complexity. The Company combines network science, machine
learning, artificial intelligence, statistics and big data with
expertise in drug discovery and development to transform the search
for new medicines and intervention strategies.
e-therapeutics has developed an in silico laboratory that
enables the rapid screening of millions of compounds and the
identification of small subsets that are enriched for highly active
hits. Its proprietary platform also has novel applications in
functional genomics, being able to analyse complex genetic
datasets, provide a deep understanding of pathological mechanisms
and distil actionable insights for the discovery of novel drugs,
biomarkers and diagnostics.
e-therapeutics has deployed and validated its disease-agnostic
drug discovery platform both in house and with partners, including
Novo Nordisk, Galapagos NV and a US-based, top 5 pharmaceutical
company.
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulations (EU) No. 596/2014 ('MAR') which has
been incorporated into UK law by the European Union (Withdrawal)
Act 2018. Upon the publication of this announcement via Regulatory
Information Service ('RIS'), this inside is now considered to be in
the public domain.
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name 1. Karl Keegan
2. Alison Gallafent
--------------------------- -----------------------------------------------
2 Reason for the notification
----------------------------------------------------------------------------
a) Position/status 1. Chief Financial Officer
2. Head of Intellectual Property
--------------------------- -----------------------------------------------
b) Initial notification/ Initial notification
Amendment
--------------------------- -----------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------------
a) Name e-therapeutics plc
--------------------------- -----------------------------------------------
b) LEI 21380049RHSSJXWKYT18
--------------------------- -----------------------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been
conducted
----------------------------------------------------------------------------
a) Description of Ordinary Shares of 0.1 pence
the financial instrument,
type of instrument ISIN: GB00B2823H99
Identification
code
--------------------------- -----------------------------------------------
b) Nature of the transaction Issue of options
--------------------------- -----------------------------------------------
c) Price(s) and volume(s) 1. 1,250,000 options over ordinary shares
at an exercise price of 12 pence each
2. 500,000 options over ordinary shares
at an exercise price of 12 pence each
--------------------------- -----------------------------------------------
d) Aggregated information 1,750,000 options
- Aggregated volume 12 pence each
- Price
--------------------------- -----------------------------------------------
e) Date of the transaction 2 June 2021
--------------------------- -----------------------------------------------
f) Place of the transaction Outside a trading venue
--------------------------- -----------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCEFLFBFQLXBBF
(END) Dow Jones Newswires
June 02, 2021 02:00 ET (06:00 GMT)
E-therapeutics (LSE:ETX)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
E-therapeutics (LSE:ETX)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024